Long-term progress of patients with chronic hepatitis B after administration of Lamivudine.
-
- IDE Tatsuya
- Second Department of Internal Medicine, Kurume University School of Medicine
-
- KUMASHIRO Ryukichi
- Second Department of Internal Medicine, Kurume University School of Medicine
-
- YANO Michitami
- Institute for Clinical Research, Nagasaki Chuo National Hospital
-
- KOGA Mitsuaki
- Institute for Clinical Research, Nagasaki Chuo National Hospital
-
- ISHIBASHI Hiromi
- Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Medicine
-
- HAYASHIDA Kazuhiro
- Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Medicine
-
- KATO Arifumi
- First Department of Internal Medicine, Nagasaki University School of Medicine
-
- NAKAO Kazuhiko
- First Department of Internal Medicine, Nagasaki University School of Medicine
-
- YAMAMOTO Kyosuke
- Department of Internal Medicine, Saga Medical School
-
- MIZUTA Toshihiko
- Department of Internal Medicine, Saga Medical School
-
- TUBOUCHI Hirohito
- Second Department of Internal Medicine, Miyazaki University School of Medicine
-
- HAYASHI Katsuhiro
- Second Department of Internal Medicine, Miyazaki University School of Medicine
-
- FURUKAWA Tetsuya
- Department of Gastroenterology, Kokura Memorial Hospital
-
- FUJIYAMA Shigetoshi
- Third Department of Internal Medicine, Kumamoto University School of Medicine
-
- CHIKAZAWA Hideto
- Third Department of Internal Medicine, Kumamoto University School of Medicine
-
- SATA Michio
- Second Department of Internal Medicine, Kurume University School of Medicine
Bibliographic Information
- Other Title
-
- Lamivudineが投与されたB型慢性肝炎の長期臨床経過
Search this article
Abstract
The long-term prognosis of 34 patients with chronic hepatitis B after administration of Lamivudine (100mg/day) for 16∼52 weeks was examined. The median of the follow-up period after the treatment was 151 week (42∼172 week). The ALT levels normalized in 8 cases (24%) after the treatment. In 3 of the 8 cases, the amount of HBV DNA was low before the treatment, the ALT levels remained normal without an increase. On the other hand, in 5 of the 8 cases, after a transient increase in the ALT levels, the levels normalized. In the other 26 cases, the ALT levels fluctuated. These results suggested that long-term treatment using Lamivudine was required in most of the cases. However, this examination suggested that the necessary condition to discontinue Lamivudine was a low amount of HBV DNA before the treatment, HBe antibody positivity during the treatment, and HBV DNA negativity during the treatment. Further examinations in a larger number of patients should be performed.
Journal
-
- Kanzo
-
Kanzo 43 (3), 137-143, 2002
The Japan Society of Hepatology
- Tweet
Keywords
Details
-
- CRID
- 1390001204790885376
-
- NII Article ID
- 10008363238
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed